Optimi Health launches Blue Serenity, Canada’s first natural therapeutic psilocybin product
Optimi Health (CSE: OPTI) has launched Canada’s first natural therapeutic psilocybin product, Blue Serenity, in collaboration with psilocybin patient advocate, Thomas Hartle. Blue Serenity contains 25 milligrams of natural psilocybin in form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms, cultivated at Optimi Health’s labs in Princeton, British Columbia. Optimi chief science officer Justin Kirkland […]
